Shadi Abu-Baker1, Zhengtao Chu2, Ashley M Stevens2, Jie Li3, Xiaoyang Qi2. 1. Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH. 2. Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH ; Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 3. Department of Dermatology, University of Miami, Miami, FL.
Abstract
Squamous cell carcinoma (SCC) and melanoma are malignant human cancers of the skin with an annual mortality that exceed 10,000 cases every year in the USA alone. In this study, the lysosomal protein saposin C (SapC) and the phospholipid dioloylphosphatidylserine (DOPS) were assembled into cancer-selective nanovesicles (SapC-DOPS) and successfully tested using several in vitro and in vivo skin cancer models. Using MTT assay that measures the percentage of cell death, SapC-DOPS cytotoxic effect on three skin tumor cell lines (squamous cell carcinoma, SK-MEL-28, and MeWo) was compared to two normal nontumorigenic skin cells lines, normal immortalized keratinocyte (NIK) and human fibroblast cell (HFC). We observed that the nanovesicles selectively killed the skin cancer cells by inducing apoptotic cell death whereas untransformed skin cancer cells remained unaffected. Using subcutaneous skin tumor xenografts, animals treated with SapC-DOPS by subcutaneous injection showed a 79.4 % tumor reduced compared to the control after 4 days of treatment. We observed that the nanovesicles killed skin cancer cells by inducing apoptotic cell death compared to the control as revealed by TUNEL staining of xenograft tumor sections.
Squamous cell carcinoma (n class="Gene">SCC) and melanoma are malignant humancancers of the skin with an annual mortality that exceed 10,000 cases every year in the USA alone. In this study, the lysosomal protein saposin C (SapC) and the phospholipid dioloylphosphatidylserine (DOPS) were assembled into cancer-selective nanovesicles (SapC-DOPS) and successfully tested using several in vitro and in vivo skin cancer models. Using MTT assay that measures the percentage of cell death, SapC-DOPS cytotoxic effect on three skin tumor cell lines (squamous cell carcinoma, SK-MEL-28, and MeWo) was compared to two normal nontumorigenic skin cells lines, normal immortalized keratinocyte (NIK) and human fibroblast cell (HFC). We observed that the nanovesicles selectively killed the skin cancer cells by inducing apoptotic cell death whereas untransformed skin cancer cells remained unaffected. Using subcutaneous skin tumor xenografts, animals treated with SapC-DOPS by subcutaneous injection showed a 79.4 % tumor reduced compared to the control after 4 days of treatment. We observed that the nanovesicles killed skin cancer cells by inducing apoptotic cell death compared to the control as revealed by TUNEL staining of xenograft tumor sections.
Authors: M Hiraiwa; S Soeda; B M Martin; A L Fluharty; Y Hirabayashi; J S O'Brien; Y Kishimoto Journal: Arch Biochem Biophys Date: 1993-06 Impact factor: 4.013
Authors: C V Hamby; R Abbi; N Prasad; C Stauffer; J Thomson; C E Mendola; V Sidorov; J M Backer Journal: Int J Cancer Date: 2000-11-15 Impact factor: 7.396
Authors: Xiaoyang Qi; Zhengtao Chu; Yonatan Y Mahller; Keith F Stringer; David P Witte; Timothy P Cripe Journal: Clin Cancer Res Date: 2009-09-08 Impact factor: 12.531
Authors: Patrick M Winter; John Pearce; Zhengtao Chu; Christopher M McPherson; Ray Takigiku; Jing-Huei Lee; Xiaoyang Qi Journal: J Magn Reson Imaging Date: 2014-05-06 Impact factor: 4.813
Authors: Mahaboob K Sulaiman; Zhengtao Chu; Victor M Blanco; Subrahmanya D Vallabhapurapu; Robert S Franco; Xiaoyang Qi Journal: Mol Cancer Date: 2015-04-08 Impact factor: 27.401
Authors: Zhengtao Chu; Shadi Abu-Baker; Mary B Palascak; Syed A Ahmad; Robert S Franco; Xiaoyang Qi Journal: PLoS One Date: 2013-10-04 Impact factor: 3.240
Authors: Subrahmanya D Vallabhapurapu; Víctor M Blanco; Mahaboob K Sulaiman; Swarajya Lakshmi Vallabhapurapu; Zhengtao Chu; Robert S Franco; Xiaoyang Qi Journal: Oncotarget Date: 2015-10-27
Authors: Víctor M Blanco; Zhengtao Chu; Subrahmanya D Vallabhapurapu; Mahaboob K Sulaiman; Ady Kendler; Olivier Rixe; Ronald E Warnick; Robert S Franco; Xiaoyang Qi Journal: Oncotarget Date: 2014-08-30